Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
2 stories have a settled next close so far (2 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$247.6B
EV / True FCF39.1x
Revenue$36.8B +10.0%
True FCF (ex-SBC)$7.6B −22.1%
Rule of 4032.0%
ROIC13.3%
True FCF Yield3.1%
EPS, diluted$14.23 +88.2%
Modern Valuation (EOD)
Market Cap$247.6B
Enterprise Value$297.6B
EV / True FCF39.13
EV / FCF36.75
EV / Gross Profit—
EV / EBIT32.78
EV / Sales8.10
P / E (GAAP)32.11
P / FCF30.56
P / Oper. CF24.86
P / Book28.59
Owner & Cash Yields
True FCF Yield3.1%
FCF Yield3.3%
Owner Earn. Yield4.3%
Earnings Yield3.1%
Shareholder Yield+1.9%
Buyback Yield0.0%
Dividend Yield2.20%
Dividend / sh$9.66
Payout Ratio67%
FCF / sh$14.97
EPS (diluted)$14.23
Compounder & Returns
Rule of 4032.0%
ROIC13.3%
Cash ROIC (CROIC)13.8%
GP / Assets—
ROE89.1%
ROA8.5%
Gross Margin—
Oper. Margin24.7%
Net Margin21.0%
FCF Margin22.0%
True FCF Margin20.7%
Quality & Dilution
Cash Conversion105%
Accrual Ratio−2.5%
SBC % of FCF6.1%
SBC % of Rev1.3%
Reinvest. Rate19%
Sales Growth Y/Y+10.0%
Sales 3Y CAGR+11.8%
EPS Growth Y/Y+88.2%
FCF Growth Y/Y−22.1%
FCF 3Y CAGR−2.7%
Share Change Y/Y+0.2%
Balance Sheet & Scale
Revenue (FY)$36.8B
Gross Profit (FY)—
Oper. Income (FY)$9.1B
GAAP Net Income$7.7B
True FCF (ex-SBC)$7.6B
Cash & Equiv$9.1B
Total Debt$59.2B
Net Cash (Debt)$-50.1B
Net Cash % MCap−20.2%
Debt / FCF (yrs)7.3y
Current Ratio1.14540.91M sh
Price & Technicals (EOD)
Perf Week−6.05%
Perf Month+0.11%
Perf Quarter−0.12%
Perf Half Y+30.05%
Perf YTD+35.50%
SMA 20 Dist−4.30%$458.53
SMA 50 Dist+2.22%$429.28
SMA 100 Dist+5.99%$414.03
Window High−8.29%$478.48
Window Low+35.50%$323.85
RSI (14) · Vol42.827%v
Income Distribution & Cash Flow ConversionHow every dollar of AMGN revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
YoY Δ
4Y CAGR
Trend
Income Statement
Revenue ▸
$26.0B
$26.3B
$28.2B
$33.4B
$36.8B
+10.0%
+9.1%
Cost of Revenue (COGS)
$6.5B
$6.4B
$8.5B
$12.9B
$12.0B
−6.4%
+16.9%
Selling, General & Admin (SG&A)
$5.4B
$5.4B
$6.2B
$7.1B
$7.0B
−0.6%
+7.1%
Operating Income (EBIT) ▸
$7.6B
$9.6B
$7.9B
$7.3B
$9.1B
+25.1%
+4.4%
Income Tax Expense
$808.0M
$794.0M
$1.1B
$519.0M
$1.3B
+143.7%
+11.9%
GAAP Net Income ▸
$5.9B
$6.6B
$6.7B
$4.1B
$7.7B
+88.5%
+7.0%
Diluted EPS ▸
$10.28
$12.11
$12.49
$7.56
$14.23
+88.2%
+8.5%
Diluted Shares
573.0M
541.0M
538.0M
541.0M
542.0M
+0.2%
−1.4%
Balance Sheet
Cash & Equivalents
$8.0B
$7.6B
$10.9B
$12.0B
$9.1B
−23.8%
+3.4%
Inventory
$4.1B
$4.9B
$9.5B
$7.0B
$6.2B
−11.0%
+11.1%
Total Current Assets
$19.4B
$22.2B
$30.3B
$29.0B
$29.1B
+0.1%
+10.6%
Total Assets
$61.2B
$65.1B
$97.2B
$91.8B
$90.6B
−1.4%
+10.3%
Total Current Liabilities
$12.2B
$15.7B
$18.4B
$23.1B
$25.5B
+10.3%
+20.3%
Total Debt (Short + Long Term)
$33.4B
$40.5B
$66.1B
$63.6B
$59.2B
−7.0%
+15.4%
Stockholders' Equity
$6.7B
$3.7B
$6.2B
$5.9B
$8.7B
+47.3%
+6.6%
Net Cash / (Net Debt)
$-25.4B
$-32.9B
$-55.1B
$-51.7B
$-50.1B
+3.1%
—
Invested Capital
$32.1B
$36.6B
$61.3B
$57.6B
$58.7B
+2.0%
+16.3%
Cash Flow & Capital Allocation
Operating Cash Flow (OCF) ▸
$9.3B
$9.7B
$8.5B
$11.5B
$10.0B
−13.3%
+1.8%
Depreciation & Amortization (D&A)
$3.4B
$3.4B
$4.1B
$5.6B
$5.2B
−7.6%
+11.0%
Stock-Based Compensation (SBC)
$341.0M
$401.0M
$431.0M
$530.0M
$494.0M
−6.8%
+9.7%
Capital Expenditures (CapEx)
$880.0M
$936.0M
$1.1B
$1.1B
$1.9B
+69.5%
+20.5%
Free Cash Flow (FCF) ▸
$8.4B
$8.8B
$7.4B
$10.4B
$8.1B
−22.1%
−0.8%
True FCF (ex-SBC Owner Cash)
$8.0B
$8.4B
$6.9B
$9.9B
$7.6B
−22.9%
−1.4%
Share Repurchases (Buybacks)
$5.0B
$6.4B
$0
$200.0M
$0
−100.0%
—
Dividends Paid
$4.0B
$4.2B
$4.6B
$4.8B
$5.1B
+6.0%
+6.3%
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.
What happened · big days
23 big days in a year, and what we hold on each
A big day is a close more than 2.99% from the one before, three times AMGN’s median day (1.00%). On 14 of the 23, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.
every other trading daya big day, numbered in the list below±2.99%Hover a bar for its day. Click a big day to open it.
Shaded: since our stories began, Jun 10. Tap a bar for its day.
#DayAMGNWhat we hold that dayGroup (median of 4) · each
1 Dec 5, 2025−3.02%
Before our storiesgroup −0.2%, did not move with it
1Dec 5, 2025−3.02%
Before our stories
−0.2% did not move with itGILD −1.1 · BIIB −0.4 · EXEL −0.0 · MRNA +8.7
2 Jan 7, 2026+3.47%
Before our storiesgroup +2.4%, moved with AMGN
2Jan 7, 2026+3.47%
Before our stories
+2.4% moved with AMGNEXEL +5.8 · GILD +2.5 · BIIB +2.4 · MRNA +0.6
3 Jan 8, 2026−3.37%
Before our storiesgroup −3.7%, moved with AMGN
3Jan 8, 2026−3.37%
Before our stories
−3.7% moved with AMGNMRNA −5.7 · EXEL −4.4 · GILD −3.0 · BIIB −0.5
4 Jan 21, 2026+3.81%
Before our storiesgroup +4.2%, moved with AMGN
4Jan 21, 2026+3.81%
Before our stories
+4.2% moved with AMGNMRNA +15.8 · BIIB +4.4 · GILD +4.0 · EXEL +2.4
5 Feb 4, 2026+8.15%
Resultsgroup +1.7%, did not move with it
5Feb 4, 2026+8.15%
ResultsFirst close after the Feb 3 results filing
+1.7% did not move with itBIIB +4.9 · GILD +2.1 · MRNA +1.4 · EXEL +0.1
6 Feb 6, 2026+4.49%
Before our storiesgroup +2.9%, moved with AMGN
6Feb 6, 2026+4.49%
Before our stories
+2.9% moved with AMGNBIIB +8.5 · EXEL +3.6 · GILD +2.1 · MRNA +0.3
7 Mar 5, 2026−3.08%
Before our storiesgroup −1.5%, did not move with it
7Mar 5, 2026−3.08%
Before our stories
−1.5% did not move with itMRNA −6.9 · GILD −2.1 · BIIB −1.0 · EXEL −1.0
8 May 1, 2026−4.75%
Resultsgroup −1.2%, did not move with it
8May 1, 2026−4.75%
ResultsFirst close after the Apr 30 results filing
−1.2% did not move with itEXEL −1.8 · MRNA −1.2 · BIIB −1.2 · GILD +0.6
9 Jun 3, 2026+3.03%
Before our storiesgroup +5.0%, moved with AMGN
9Jun 3, 2026+3.03%
Before our stories
+5.0% moved with AMGNMRNA +7.5 · EXEL +6.3 · BIIB +3.8 · GILD +1.1
10 Jun 11, 2026+4.84%
Nothing on AMGNgroup +3.3%, moved with AMGN
10Jun 11, 2026+4.84%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+3.3% moved with AMGNMRNA +7.9 · GILD +3.6 · BIIB +2.9 · EXEL +1.8
11 Jul 2, 2026+3.55%
Nothing on AMGNgroup +3.9%, moved with AMGN
11Jul 2, 2026+3.55%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+3.9% moved with AMGNMRNA +10.0 · GILD +4.2 · EXEL +3.5 · BIIB +3.0
12 Jul 16, 2026+3.70%
Nothing on AMGNgroup +1.9%, moved with AMGN
12Jul 16, 2026+3.70%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+1.9% moved with AMGNBIIB +5.9 · GILD +3.5 · EXEL +0.2 · MRNA −7.5
13 Jul 28, 2026+4.48%
Nothing on AMGNgroup +2.0%, did not move with it
13Jul 28, 2026+4.48%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+2.0% did not move with itGILD +2.9 · BIIB +2.7 · EXEL +1.3 · MRNA +0.3
14 Aug 5, 2026+4.57%
Resultsgroup −1.1%, did not move with it
14Aug 5, 2026+4.57%
ResultsFirst close after the Aug 4 results filing
−1.1% did not move with itEXEL +1.3 · BIIB −0.9 · MRNA −1.3 · GILD −2.6
15 Aug 19, 2026+4.02%
Nothing on AMGNgroup +3.6%, moved with AMGN
15Aug 19, 2026+4.02%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+3.6% moved with AMGNMRNA +177.0 · BIIB +4.2 · GILD +2.9 · EXEL +2.4
−3.2% did not move with itBIIB −3.8 · MRNA −3.6 · GILD −2.9 · EXEL −2.3
17 Sep 22, 2026+4.34%
Nothing on AMGNgroup +2.3%, moved with AMGN
17Sep 22, 2026+4.34%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+2.3% moved with AMGNMRNA +5.6 · BIIB +2.9 · EXEL +1.6 · GILD +1.4
18 Oct 1, 2026−3.38%
Nothing on AMGNgroup −1.2%, did not move with it
18Oct 1, 2026−3.38%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
−1.2% did not move with itMRNA −1.9 · BIIB −1.4 · GILD −1.0 · EXEL −0.8
19 Oct 14, 2026+3.21%
Nothing on AMGNgroup +3.1%, moved with AMGN
19Oct 14, 2026+3.21%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+3.1% moved with AMGNMRNA +4.7 · GILD +3.8 · EXEL +2.5 · BIIB +1.7
20 Oct 20, 2026+3.29%
Nothing on AMGNgroup +3.4%, moved with AMGN
20Oct 20, 2026+3.29%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
+3.4% moved with AMGNMRNA +6.7 · BIIB +4.1 · EXEL +2.7 · GILD +2.3
21 Nov 4, 2026+3.73%
Resultsgroup +3.2%, moved with AMGN
21Nov 4, 2026+3.73%
ResultsFirst close after the Nov 3 results filing
+3.2% moved with AMGNMRNA +13.1 · GILD +4.2 · BIIB +2.2 · EXEL +0.6
22 Nov 5, 2026−3.80%
Nothing on AMGNgroup −4.8%, moved with AMGN
22Nov 5, 2026−3.80%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
−4.8% moved with AMGNMRNA −6.5 · EXEL −5.5 · BIIB −4.1 · GILD −4.0
23 Nov 18, 2026−3.07%
Nothing on AMGNgroup −0.5%, did not move with it
23Nov 18, 2026−3.07%
Nothing on AMGNNo AMGN story, brief or results filing in our record that day
−0.5% did not move with itMRNA −4.8 · GILD −0.8 · EXEL −0.3 · BIIB +0.3
A story on the same day is not a cause, and a group move is not proof either. Group: the median of GILD, MRNA, BIIB and EXEL that day, the largest companies in AMGN’s SEC industry; “moved with AMGN” means the same direction and at least half the size.
What’s next · results
Before the next report: what the first day after the last four did
Six trading days after each results filing (SEC 8-K, Item 2.02). AMGN reports after the close, so day 1 is the next close. Each time, day 6 ended on the same side as day 1.
Reported Feb 3, 2026
day 1+8.15%day 6+8.27%
Reported Apr 30, 2026
day 1−4.75%day 6−4.20%
Reported Aug 4, 2026
day 1+4.57%day 6+6.71%
Reported Nov 3, 2026
day 1+3.73%day 6+1.49%
Next report: expected early FebruaryEstimated from the dates of its last four results filings. Not announced. Since the Nov 3 report: −3.77%. Four reports is a small sample.
Each line is AMGN’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.
Same industry
AMGN against four biotech peers, a year at 100
AMGN is up 31.5% in a year. Moderna is up 8.3 times, Exelixis is up 60.6%, Biogen 43.4% and Gilead Sciences 33.4%. All four did more. Weekly closes, Nov 21, 2025 = 100, on a log scale so a 8.3-fold rise and a 31.5% rise both read honestly.
End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in AMGN’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.